Heart Failure

Why US patients are now in absolute need of proven measures to lessen their risk of cardiovascular burden.

What more needs to be learned about the link between the 2 diseases?

A conversation with Deepak Bhatt, MD, MPH, discussing the most impactful advances in cardiology in 2019 and what he sees as the most important advances in the past decade as 2019 comes to a close.

How preventive care strategy adherence could bolster heart disease risk reduction in entire families.

A fourth-year cardiology medical student shares his perspectives from the audience at the American Heart Association Scientific Sessions.

New empagliflozin data assesses the SGLT-2 inhibitor versus GLP-1 agonists and DPP-4 inhibitors for patients with heart failure.

The adult heart failure study is the first of its kind: a completely decentralized, indication-seeking clinical trial.

George Bakris, MD, discusses how nephrologists can work with other specialists and what the highlight of Kidney Week was.

George Bakris, MD, discusses the major study during Kidney Week, as well as what diseases should get more attention in future research.

During Kidney Week, investigators present data showing that canagliflozin could be beneficial for patients across various levels of kidney function.

Of the predominating risk factors or comorbidities that occur with HF, hypertension appears to be the most prevalent.

AstraZeneca announced approval of the SGLT2 inhibitor for the reduction of hospitalization for heart failure in type 2 diabetes patients in a release on Monday.

Far and away, cardiovascular disease is the greatest killer of people in the US. At the crux of it is heart failure, an often misunderstood condition in need of improved options.

African Americans are more greatly burdened by the cardiovascular condition and its common comorbidities. Are new therapies able to help?

The Biovitals Analytics Engine is able to read physiology signals to allow doctors to change the trajectory of disease weeks in advance.

Its approval was based on findings from the limited assessment of pediatric patients in PANORAMA-HF, showing reduction of a cardiovascular biomarker.

The diabetes management and adult health specialist reacts to the SGLT2 inhibitor's newest indication.

A study from cardiologists at UPMC Children's Hospital of Pittsburgh examining changes to criteria in 2016, which aimed to improve mortality rates among pediatric candidates for heart transplantation, found rates have worsened for certain conditions.

While better therapies exist to treat patients with heart failure with reduced ejection fraction, there are several hurdles preventing them from being implemented.

Doctors need to use their best judgement when deciding when to use cardiogenic shock devices for temporary mechanical support.

A new American Heart Association and National Institutes of Health-sponsored study found that use of a polypill reduced cardiovascular risk in a low-income population in Mobile, Alabama.

How recent trends in heart failure research have shown more priority to patient quality of life outcomes.